NewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $48.00 target price on the stock.

A number of other research analysts have also recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Piper Sandler reiterated an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $38.17.

NewAmsterdam Pharma Trading Down 2.4 %

Shares of NAMS opened at $23.42 on Tuesday. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29. The business’s fifty day moving average is $23.67 and its 200-day moving average is $19.77.

Insider Activity

In other news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 446,730 shares of company stock valued at $11,438,695. 19.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP raised its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares during the last quarter. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new stake in NewAmsterdam Pharma in the third quarter valued at $128,000. HB Wealth Management LLC bought a new position in NewAmsterdam Pharma during the 4th quarter worth $224,000. Finally, XTX Topco Ltd acquired a new position in NewAmsterdam Pharma during the 3rd quarter worth about $187,000. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.